CSPC Pharmaceutical Group's (HKG:1093) investigational new drug application to conduct a clinical trial of SYS6043 has been approved by the U.S. Food and Drug Administration (FDA), a Thursday bourse filing said.
The indication for this approval is advanced/metastatic solid tumors, and the drug is expected to be indicated for the treatment of small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, prostate cancer, and hepatocellular carcinoma.
The pharmaceutical company obtained clinical trial approval from the National Medical Products Administration of China in December 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.